Neuropace Inc (NPCE)

$7.51

-0.51

(-6.36%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $7.24
    $8.13
    $7.51
    downward going graph

    3.6%

    Downside

    Day's Volatility :10.95%

    Upside

    7.63%

    downward going graph
  • $3.91
    $18.15
    $7.51
    downward going graph

    47.94%

    Downside

    52 Weeks Volatility :78.46%

    Upside

    58.62%

    downward going graph

Returns

PeriodNeuropace IncSector (Health Care)Index (Russel 2000)
3 Months
-46.36%
8.7%
0.0%
6 Months
-43.32%
8.0%
0.0%
1 Year
71.07%
14.0%
0.0%
3 Years
-67.15%
17.0%
-18.2%

Highlights

Market Capitalization
230.7M
Book Value
$0.5
Earnings Per Share (EPS)
-1.18
Wall Street Target Price
17.0
Profit Margin
-45.61%
Operating Margin TTM
-41.63%
Return On Assets TTM
-16.09%
Return On Equity TTM
-150.63%
Revenue TTM
69.1M
Revenue Per Share TTM
2.59
Quarterly Revenue Growth YOY
25.2%
Gross Profit TTM
32.5M
EBITDA
-26.2M
Diluted Eps TTM
-1.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.15
EPS Estimate Next Year
-1.03
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Neuropace Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 126.36%

Current $7.51
Target $17.00

Company Financials

FY19Y/Y Change
Revenue
37.0M
-
Net Income
-40.7M
-
Net Profit Margin
-110.19%
-
FY20Y/Y Change
Revenue
41.1M
↑ 11.27%
Net Income
-36.0M
↓ 11.68%
Net Profit Margin
-87.47%
↑ 22.72%
FY21Y/Y Change
Revenue
45.2M
↑ 9.83%
Net Income
-38.1M
↑ 5.91%
Net Profit Margin
-84.34%
↑ 3.13%
FY22Y/Y Change
Revenue
45.5M
↑ 0.75%
Net Income
-53.4M
↑ 40.05%
Net Profit Margin
-117.25%
↓ 32.91%
FY23Y/Y Change
Revenue
65.4M
↑ 43.72%
Net Income
-33.0M
↓ 38.25%
Net Profit Margin
-50.38%
↑ 66.87%
Q4 FY22Q/Q Change
Revenue
12.8M
↑ 14.63%
Net Income
-12.4M
↓ 7.02%
Net Profit Margin
-97.22%
↑ 22.62%
Q1 FY23Q/Q Change
Revenue
14.5M
↑ 13.16%
Net Income
-14.4M
↑ 15.79%
Net Profit Margin
-99.47%
↓ 2.25%
Q2 FY23Q/Q Change
Revenue
16.5M
↑ 14.08%
Net Income
-9.1M
↓ 36.62%
Net Profit Margin
-55.26%
↑ 44.21%
Q3 FY23Q/Q Change
Revenue
16.4M
↓ 0.5%
Net Income
-7.3M
↓ 20.46%
Net Profit Margin
-44.18%
↑ 11.08%
Q4 FY23Q/Q Change
Revenue
18.0M
↑ 9.65%
Net Income
-6.2M
↓ 14.57%
Net Profit Margin
-34.42%
↑ 9.76%
Q1 FY24Q/Q Change
Revenue
18.1M
↑ 0.62%
Net Income
-8.9M
↑ 43.95%
Net Profit Margin
-49.24%
↓ 14.82%
FY19Y/Y Change
Total Assets
21.1M
-
Total Liabilities
150.4M
-
FY20Y/Y Change
Total Assets
56.0M
↑ 165.23%
Total Liabilities
203.8M
↑ 35.45%
FY21Y/Y Change
Total Assets
133.6M
↑ 138.72%
Total Liabilities
60.1M
↓ 70.53%
FY22Y/Y Change
Total Assets
114.1M
↓ 14.57%
Total Liabilities
79.3M
↑ 32.09%
FY23Y/Y Change
Total Assets
107.7M
↓ 5.66%
Total Liabilities
87.0M
↑ 9.67%
Q4 FY22Q/Q Change
Total Assets
114.1M
↓ 5.29%
Total Liabilities
79.3M
↑ 2.94%
Q1 FY23Q/Q Change
Total Assets
106.3M
↓ 6.87%
Total Liabilities
78.8M
↓ 0.69%
Q2 FY23Q/Q Change
Total Assets
102.2M
↓ 3.8%
Total Liabilities
81.0M
↑ 2.82%
Q3 FY23Q/Q Change
Total Assets
99.3M
↓ 2.87%
Total Liabilities
82.9M
↑ 2.38%
Q4 FY23Q/Q Change
Total Assets
107.7M
↑ 8.41%
Total Liabilities
87.0M
↑ 4.9%
Q1 FY24Q/Q Change
Total Assets
98.9M
↓ 8.17%
Total Liabilities
84.5M
↓ 2.86%
FY19Y/Y Change
Operating Cash Flow
-25.0M
-
Investing Cash Flow
3.6M
-
Financing Cash Flow
21.4M
-
FY20Y/Y Change
Operating Cash Flow
-21.6M
↓ 13.65%
Investing Cash Flow
-10.8M
↓ 397.6%
Financing Cash Flow
55.0M
↑ 157.41%
FY21Y/Y Change
Operating Cash Flow
-24.6M
↑ 13.74%
Investing Cash Flow
-85.4M
↑ 693.13%
Financing Cash Flow
102.5M
↑ 86.38%
FY22Y/Y Change
Operating Cash Flow
-36.9M
↑ 50.01%
Investing Cash Flow
23.8M
↓ 127.87%
Financing Cash Flow
490.0K
↓ 99.52%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.8M
↑ 12.44%
Investing Cash Flow
8.9M
↑ 27.68%
Financing Cash Flow
-138.0K
↑ 1625.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.7M
↑ 23.65%
Investing Cash Flow
10.1M
↑ 13.15%
Financing Cash Flow
-255.0K
↑ 84.78%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.4M
↓ 55.04%
Investing Cash Flow
5.3M
↓ 47.36%
Financing Cash Flow
195.0K
↓ 176.47%

Technicals Summary

Sell

Neutral

Buy

Neuropace Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neuropace Inc
Neuropace Inc
15.54%
-43.32%
71.07%
-67.15%
-69.91%
Stryker Corporation
Stryker Corporation
-4.02%
6.33%
12.81%
34.45%
59.01%
Boston Scientific Corp.
Boston Scientific Corp.
1.44%
26.8%
46.58%
87.75%
81.54%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-1.37%
17.29%
-5.09%
-15.16%
35.66%
Abbott Laboratories
Abbott Laboratories
0.66%
-8.19%
-2.12%
-11.88%
19.28%
Medtronic Plc
Medtronic Plc
1.89%
-5.83%
-6.17%
-33.8%
-19.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neuropace Inc
Neuropace Inc
NA
NA
NA
-1.15
-1.51
-0.16
NA
0.5
Stryker Corporation
Stryker Corporation
38.02
38.02
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.66
65.66
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.63
37.63
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.9
31.9
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.3
28.3
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neuropace Inc
Neuropace Inc
Buy
$230.7M
-69.91%
NA
-45.61%
Stryker Corporation
Stryker Corporation
Buy
$127.0B
59.01%
38.02
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.9B
81.54%
65.66
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.9B
35.66%
37.63
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$178.7B
19.28%
31.9
13.96%
Medtronic Plc
Medtronic Plc
Buy
$100.1B
-19.81%
28.3
11.36%

Insights on Neuropace Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 16.42M → 18.12M (in $), with an average increase of 4.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -6.2M → -8.92M (in $), with an average decrease of 44.0% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 83.9% return, outperforming this stock by 151.7%

Institutional Holdings

  • Orbimed Advisors, LLC

    13.92%
  • Morgan Stanley - Brokerage Accounts

    8.63%
  • Soleus Capital Management, L.P.

    8.46%
  • Nantahala Capital Management, LLC

    2.71%
  • Kent Lake Capital LLC

    2.24%
  • Millennium Management LLC

    2.11%

Company Information

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

Organization
Neuropace Inc
Employees
181
CEO
Dr. Martha J. Morrell
Industry
Healthcare

FAQs